



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/09</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/58657</b> <b>(43) International Publication Date:</b> 30 December 1998 (30.12.98)
<b>(21) International Application Number:</b> PCT/EP98/03713 <b>(22) International Filing Date:</b> 16 June 1998 (16.06.98) <b>(30) Priority Data:</b> 97201885.7 20 June 1997 (20.06.97) EP <i>(34) Countries for which the regional or international application was filed:</i> NL et al. <b>(71) Applicant (for all designated States except US):</b> AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MANNAERTS, Bernadette, Maria, Julia, Louise [NL/NL]; Acacialaan 24, NL-5384 BB Heesch (NL). COELINGH BENNINK, Herman, Jan, Tijmen [NL/NL]; Melvillvan Carnebeeklaan 38, NL-3971 BE Driebergen (NL). ORLEMANS, Everardus, Otto, Maria [NL/NL]; Wolfespoor 12, NL-5343 XM Oss (NL). <b>(74) Agent:</b> KRAAK, H.; P.O. Box 20, NL-5340 BH Oss (NL).		<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> GONADOTROPIN RELEASING HORMONE ANTAGONIST  <b>(57) Abstract</b>  <p>The present invention relates to a method to prevent a premature LH surge. The method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount between 0.125 – 1 mg in combination with exogenous FSH. The method can be used in the treatment of women undergoing controlled ovarian superovulation.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Gonadotropin releasing hormone antagonist

5       The present invention relates to a pharmaceutical preparation useful in controlled ovarian hyperstimulation (COH) as well as to a method to prevent a premature LH surge.

10       The glycoprotein hormones Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) are released from the pituitary gland under control of Gonadotropin Releasing Hormone (GnRH). They act on the ovary to stimulate steroid synthesis and secretion and thus play a central role in the reproductive cycle.

15       In the normal cycle, there is a mid-cycle surge in LH concentration which is followed by ovulation. The LH surge is a consequence of the raise in estrogen levels brought about by the endogenous secretion of LH and FSH. The estrogen is part of a positive feedback mechanism resulting in the elevated LH level.

20       GnRH analogues are useful for a variety of disorders in which immediate reversible suppression of the pituitary-gonadal axis is desired. This can in principle be achieved with GnRH agonists as well as with GnRH antagonists. In comparison to GnRH agonists, GnRH antagonists have the advantage of not inducing an initial release of gonadotropins (flare-up) and steroids before suppression.

25       Currently, GnRH agonists are clinically applied for the prevention of endogenous LH-surges during controlled ovarian hyperstimulation for Assisted Reproduction Techniques (ART). Specific disadvantages of GnRH agonists are the initial flare-up and the rather long period until pituitary suppression becomes effective. Usually, patients undergoing COH start only  
30       treatment with (recombinant) FSH after 2 to 3 weeks pretreatment with GnRH agonists.

Women treated for this purpose without GnRH analogues, all show attenuated LH rises irrespective of the treatment schedule used. Usually these rises occur prematurely due to a positive feedback of rising estradiol (E2) produced by a cohort of relative small follicles. The exposure of non-mature follicles to high levels of LH leads to premature luteinisation of granulosa cells and hence to increased production of progesterone and decreased synthesis of E2. These changes lead to disrupted maturation and decreased fertilization and implantation rates. Success rates of COH cycles in which premature LH rises are detected, are reported to be low and often these cycles are canceled because the number and/or size of follicles is still too small.

The suppressive potency of GnRH agonist treatment in women with normal menstrual cycles may depend on structure-receptor interaction, elimination half-life dosage and route of administration of the specific GnRH agonist applied. Clinical studies with different regimens of GnRH agonists have clearly demonstrated that the amount of remaining LH in women undergoing COH is always sufficient to support folliculogenesis and estrogen biosynthesis induced by pure FSH. In these studies the minimum amount of circulating endogenous LH was only 1 to 2 IU/L. In some women LH concentrations dropped below 0.5 IU/L but still FSH treatment appeared to be effective.

In contrast to GnRH agonists, GnRH antagonists by GnRH receptor competition provide an immediate inhibition of gonadotropin secretion, especially of LH. Thus, during COH by FSH, GnRH antagonist treatment is only required during the few days when there is an increased risk for a premature LH surge.

The present invention relates to the use of the antagonist ganirelix which has the following chemical name:

N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-N<sup>9</sup>,N<sup>10</sup>-diethyl-D-homoarginyl-L-leucin-N<sup>9</sup>,N<sup>10</sup>-diethyl-L-

homoarginyl-L-propyl-D-alanylamine acetate. The abbreviated structure is [N-Ac-D-Na(2)<sup>1</sup>,D-pClPhe<sup>2</sup>,D-Pal(3)<sup>3</sup>,D-hArg(Et<sub>2</sub>)<sup>6</sup>,L-hArg(Et<sub>2</sub>)<sup>8</sup>,D-Ala<sup>10</sup>-GnRH.

In a phase I study, published by Nelson et al., 1995, rapid, profound, reversible suppression of the pituitary-gonadal axis was obtained in reproductive age women. In this study women started on days 6 to 9 of the menstrual cycle with a daily SC injection of 1 mg or 2 mg of GnRH ganirelix for 8 consecutive days. Nelson et al demonstrated that maximal mean LH suppression was approximately 60% at 8 h after the first injection and that at that time point LH levels were 4 to 5 IU/L. During the treatment period, serum LH measured just prior to the following administration of ganirelix remained at steady state (5 to 6 IU/L) at a dose of 2 mg ganirelix whereas those treated with 1 mg ganirelix showed slowly increasing concentrations of endogenous LH (from 6 to 9 IU/L)

The GnRH antagonist ganirelix is disclosed in US patent No. 4,801,577 for nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists. This patent, which is fully incorporated herein by reference, describes the method for the preparation of these compounds. It is indicated that the compounds described therein can be used for the prevention of ovarian hyperstimulation. For human therapy a daily range is suggested for administration of the active ingredient between 0.001 and 5 mg/kg body weight, preferably between 0.01 and 1 mg/kg.

Surprisingly, however, clinical experiments have indicated that the dosage range is very narrow and that a deviation from this range is either leading to premature LH rises or to too much suppression of endogenous LH and as a consequence of estrogen biosynthesis. Accordingly, the implantation rate is unacceptable low. In contrast, a daily dose between 0.125 mg and 1 mg of ganirelix per subject on one hand prevents premature LH rises to occur and at the same time maintains sufficient LH to support follicular maturation and estrogen biosynthesis, both required to ensure successful treatment outcome.

The invention therefore relates to a pharmaceutical preparation comprising ganirelix in an amount which is at least 0.125 mg but less than 1 mg. Preferably the amount is about 0.25 mg. This preparation is useful in the treatment of women undergoing COH.

5 The preparation is administered together with FSH during the days of ovarian stimulation when a premature LH rise may easily occur e.g. from day 5 of FSH administration onwards. The preparation in its proposed dosage range has the advantage of providing an immediate effect that prevents an LH surge and at the same time maximizes the chances of establishing  
10 pregnancy. Administration is usually stopped when sufficient follicles have matured and exogenous hCG/LH is given for induction of ovulation.

The exact regimen for administration might depend on the individual response and is finally to be decided by the clinician who treats the subject. For this reason the duration of initial ovarian stimulation with FSH alone as  
15 well as the duration of combined treatment with FSH/GnRH antagonist treatment may vary. FSH treatment usually starts at menses day 1, 2 or 3. Ovarian stimulation with FSH alone may be continued up to 5 days in an amount of 150-225 IU. FSH is administered preferably as a recombinant protein. Treatment with GnRH antagonist may be started at the first day of  
20 FSH, but preferably such treatment starts at FSH treatment day 4 or 5. The GnRH antagonist is administered in the amount as indicated in combination with FSH in amounts between 75 - 600 IU, preferably between 150 - 300 IU. GnRH antagonist treatment may last 2 - 14 days i.e. up to the moment whereupon the patient is treated with exogenous LH/hCG for ovulation  
25 induction.

According to another aspect of the invention ganirelix in an amount of 0.125 - 1 mg is used for the manufacture of a medicament to prevent a premature LH surge in women undergoing controlled ovarian  
30 hyperstimulation.

The pharmaceutical preparations for use according to the invention can be prepared in accordance with standard techniques such as for example are described in the standard reference, Gennaro et al. (Ed.), Remington's

Pharmaceutical Sciences, (18<sup>th</sup> ed. Mack Publishing Company, 1990, e.g. Part 8: Pharmaceutical Preparations And Their Manufacture). For the purpose of making the pharmaceutical preparations according to the invention, the active substance is mixed with or dissolved in a pharmaceutical acceptable carrier.

Any conventional pharmaceutical carrier that does not interfere with performance of the active ingredient can be used in the preparations according to the present invention. Formulations may contain as common excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated napthalenes and the like.

The pharmaceutical preparation may be administered parenterally. Preferably it is administered subcutaneously, particularly in the form of liquid solutions or suspensions. A typical formulation is a solution containing, in addition to the active substance in an amount of 0.125 - 1 mg, glacial acetic acid, mannitol, and water adjusted to pH 5 with sodium hydroxide and / or hydrochloric acid. Optionally preservations such as e.g. methyl- and propylparaben can be added. The solutions can be packaged e.g. in glass vials or in syringes.

#### Legends to the Figures

Figure 1: Miscarriage rate and Ectopic pregnancy rate per treatment for each dosage group of ganirelix.

Figure 2: Vital Pregnancy rate per attempt (those who starting hormonal treatment) and per transfer (those who indeed had a embryo transfer) for each dosage group of ganirelix.

### Examples

In order to establish the minimum effective dose of ganirelix to prevent premature LH surges in women undergoing COH with recombinant FSH, a double-blind dose-finding study was performed with 6 test doses ranging between 2 mg and 0.0625 mg ganirelix.

This study was a phase II, multi-centre, double-blind, randomized, dose-finding study to assess the efficacy of the GnRH-antagonist ganirelix to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation with recFSH. The dosages of ganirelix are administered by one daily SC administration.

RecFSH treatment started on day 2 of the menstrual cycle (treatment day -5) by a once daily SC injection. From treatment day -5 through day -1 the dose of recFSH was fixed at 150 IU daily. After 5 days of recFSH treatment (day 7 of the menstrual cycle), ganirelix treatment was started by daily SC administration. Treatment continued until and including the last day of recFSH administration. During ganirelix treatment, the dose of recFSH was adjusted depending on the individual ovarian response as assessed by daily ultrasonographic scan (USS). As soon as at least 3 follicles  $\geq 17$  mm measured by USS were observed, hCG was administered for ovulation induction. About 30 - 36 hours thereafter oocyte pick-up was performed followed by IVF with or without ICSI. No more than 3 embryos were replaced.

If during ganirelix treatment a premature LH rise occurred e.g. at least one value of serum LH  $\geq 15$  IU/L according to the local LH immunoassay the investigator canceled the cycle or tried to rescue the cycle by giving hCG prematurely. In addition, the investigator notified the sponsor about the occurrence of the LH rise and the central laboratory was requested to confirm the LH rise was  $\geq 10$  IU/L according to the central LH immunoassay. Subsequently, all data of such subject with a premature LH rise were forwarded to an Independent Advisory Committee which was installed in order to advice on stopping a treatment arm in case of LH rises during ganirelix treatment.



During the study, some investigators informed the sponsor on one or more cases of extremely low serum LH and falling estradiol concentrations as well as follicle growth arrest after starting ganirelix treatment. For this reason the External Independent Advisory Committee was requested to review all clinical data available in order to evaluate whether these observations were dose related and whether, in their opinion, there was reason to stop one or more treatment arms.

In addition, the Independent Advisory Committee reviewed all rises of LH ( $\geq 15$  IU/L according to the local LH immunoassay and  $\geq 10$  IU/L according to the central LH immunoassay) during ganirelix treatment. Based on their evaluation the External Committee advised the sponsor to stop the highest (2 mg) and lowest (0.0625 mg) treatment dose of ganirelix. The study was completed for the other dosage groups.

In total 333 subjects started recFSH treatment and 332 subjects started ganirelix treatment. Because of major protocol violation 3 subjects were excluded from the analysis. The final number of patients per dosing group are included in Table 1.

Serum ganirelix concentration increased in a dose-proportional manner and showed a negative relationship with serum LH concentrations. The lowest dose of 0.0625 mg ganirelix could not prevent LH rises to occur in 5 out of 31 subjects (16%) (see Table 1).

During ovarian stimulation with FSH increases of serum estradiol were lower with increasing doses of ganirelix. Accordingly, at the day of hCG, median LH and estradiol values were most decreased in the 2 mg group resulting in very low values of 0.34 IU/L and 430 pg/ml, respectively (see Table 2). In this group 4 women were switched during ovarian stimulation from FSH to hMG (human menopausal gonadotropin) to increase LH concentrations and to ensure sufficient estrogen production. Although a similar number of good quality embryos was obtained and used for transfer, in the 2 mg dose group the miscarriage rate was highest (13%) and the vital pregnancy rate was

lowest i.e. 3.8% per attempt and 4.3% per transfer (see Figures 1 and 2).

Table 1. Incidence of LH rises in the different ganirelix dosage groups.

Dose group	0.0625 mg N=31	0.125 mg N=65	0.25 mg N=69	0.5 mg N=69	1 mg N=65	2 mg N=30
	5 (16%)	6 (9.2%)	1 (1.4%)	0	0	0

5

Table 2. Median serum hormone values at the day of hCG (= last day of ganirelix)

Hormone value	0.0625 mg	0.125 mg	0.25 mg	0.5 mg	1 mg	2 mg
FSH IU/L	9.1	9.0	9.1	10.2	9.8	8.8
LH IU/L	3.56	2.46	1.73	1.02	0.57	0.34
E <sub>2</sub> pg/ml	1475	1130	1160	823	703	430

10

Claims

- 5 1. A pharmaceutical preparation comprising ganirelix in an amount of at least 0.125 mg and less than 1 mg.
2. A pharmaceutical preparation comprising ganirelix in an amount of 0.25 mg.
- 10 3. Use of ganirelix in an amount of 0.125 - 1 mg for the manufacture of a medicament to prevent a premature LH surge in women undergoing controlled ovarian hyperstimulation.
4. Method to prevent a premature LH surge in women undergoing controlled ovarian hyperstimulation by administration of exogenous FSH comprising administering FSH conjointly with the preparation according to claims 1 or 2.

15

Figure 1





Figure 2  
Pregnancy rate %



# INTERNATIONAL SEARCH REPORT

In ational Application No

PCT/EP 98/03713

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/09

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 801 577 A (NESTOR JR JOHN J ET AL) 31 January 1989 cited in the application see column 11, line 30 - column 14, line 58 ---	1-3
X	LINDA R. NELSON ET AL.: "SUPPRESSION OF FOLLICULAR PHASE PITUITARY-GONADAL FUNCTION BY A POTENT NEW GONADOTROPIN-RELEASING HORMONE ANTAGONIST WITH REDUCED HISTAMINE-RELEASING PROPERTIES (GANIRELIX)" FERTILITY AND STERILITY, vol. 63, no. 5, May 1995, pages 963-969, XP002049487 cited in the application see the whole document --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### ° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 October 1998

Date of mailing of the international search report

29/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

# INTERNATIONAL SEARCH REPORT

In. ational Application No

PCT/EP 98/03713

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VICTOR Y. FUJIMOTO ET AL.: "DOSE-RELATED SUPPRESSION OF SERUM LUTEINIZING HORMONE IN WOMEN BY A POTENT NEW GONADOTROPIN-RELEASING HORMONE ANTAGONIST (GANIRELIX) ADMINISTRED BY INTRANASAL SPRAY"  FERTILITY AND STERILITY,  vol. 67, no. 3, March 1997, pages 469-473,  XP002049488  see the whole document  -----</p>	1-3



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/03713

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/EP 98/03713

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4801577 A	31-01-1989	AT 109159 T	15-08-1994
		AU 614275 B	29-08-1991
		AU 1126588 A	11-08-1988
		CA 1339043 A	01-04-1997
		DE 3850789 D	01-09-1994
		DE 3850789 T	09-03-1995
		DK 57288 A	06-08-1988
		EP 0277829 A	10-08-1988
		ES 2056908 T	16-10-1994
		FI 880509 A,B,	06-08-1988
		FI 930694 A,B,	17-02-1993
		HK 35997 A	27-03-1997
		HU 9500080 A	28-04-1995
		IE 63707 B	31-05-1995
		JP 2061562 C	10-06-1996
		JP 7091314 B	04-10-1995
		JP 63201199 A	19-08-1988
		MX 9202737 A	30-06-1992
		NO 176440 B	27-12-1994
		NO 301014 B	01-09-1997
		US 5767082 A	16-06-1998